Impact of HER2 Amplification in Colorectal Cancer

Publication
Video
Special ReportsGastrointestinal Cancers: mCRC (Issue 9)
Volume 1
Issue 9

Kanwal Raghav,MBBS, MD, Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, the University of Texas M.D. Anderson Cancer Center, discusses HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.

Kanwal Raghav,MBBS, MD, Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, the University of Texas M.D. Anderson Cancer Center, discusses HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.

Articles in this issue
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Role of DPR in Colorectal Cancer
Role of DPR in Colorectal Cancer
Overview of the Lume 1 and 2 Trials
Overview of the Lume 1 and 2 Trials
Impact of HER2 Amplification in Colorectal Cancer
Impact of HER2 Amplification in Colorectal Cancer
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
Novel Immunotherapy Combinations on Horizon for mCRC
Novel Immunotherapy Combinations on Horizon for mCRC
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Immunotherapy Duo Shows 42% 2-Year Survival in MSS CRC Trial

Immunotherapy Duo Shows 42% 2-Year Survival in MSS CRC Trial

Sabrina Serani
July 15th 2025
Article

Agenus reveals promising survival rates for its immunotherapy in metastatic colorectal cancer, potentially transforming treatment for resistant patients.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

TROP-2 Inhibitors Are Explored in Breast Cancer

TROP-2 Inhibitors Are Explored in Breast Cancer

Tony Berberabe, MPH
June 28th 2025
Article

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

Reducing Costs and Readmissions Through Data Analytics in Health Care

Reducing Costs and Readmissions Through Data Analytics in Health Care

Stephan Hawke
June 26th 2025
Article

Discover how data analytics transforms health care by reducing costs, improving patient outcomes, and enhancing operational efficiency through innovative technologies.

Read More

Earlier Use of Pembrolizumab Is Advocated in HNSCC

Earlier Use of Pembrolizumab Is Advocated in HNSCC

Robert L. Ferris, MD, PhD
June 25th 2025
Article

Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier immunotherapy integration and future treatment strategies.

Read More